Mr. Michal Efraty reports

NEUROTHERA LABS ANNOUNCES UPSIZE TO PRIVATE PLACEMENT

Neurothera Labs Inc., further to its news release dated June 30, 2026, has increased the size of its previously announced non-brokered private placement and extended the expiry term of the unit warrants (as defined below). The company now intends to issue up to 45 million units at a price of 12 Canadian cents per offered unit for gross proceeds of up to approximately $5.4-million (Canadian) under the offering.

Each offered unit will comprise one common share in the capital of the company and one transferable common share purchase warrant, entitling the holder thereof to acquire one common share in the capital of the company at a U.S.-dollar exercise price equivalent to 16 Canadian cents per unit warrant share (to be calculated on the date of closing of the offering) for a period of 36 months from the date of issuance thereof, an increase to the previously announced 24-month expiry period for the unit warrants. The unit warrants will also have an acceleration provision whereby upon the securities of Neurothera being approved for trading on the Nasdaq Stock Market, Neurothera will accelerate the expiry date of 50 per cent of the unexercised unit warrants.

The company intends to use the net proceeds of the offering for general working capital purposes, including the evaluation of prospective transactions, settlement of liabilities, including repayment of outstanding indebtedness owed to SciSparc Ltd. and other corporate and administrative expenses.

The unit shares and unit warrants issued under the offering will be subject to a statutory hold period expiring four months and one day from the date of issuance of such offered units.

The company may pay finders' fees on a portion of the offering, subject to applicable securities legislation. Closing of the offering is subject to approval of the TSX Venture Exchange. It is not anticipated that any new insiders will be created, nor that any change of control will occur, as a result of the offering. Any participation by insiders of the company in the offering will be on the same terms as arm's-length investors.

About Neurothera Labs Inc.

Neurothera Labs is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

We seek Safe Harbor.